Emerging Disease News and Research

RSS

Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program

Infinity Pharmaceuticals, Inc. today announced that Purdue Pharmaceutical Products L.P. and its independent associated company, Mundipharma International Corporation Ltd., have exercised their right to assume worldwide development and commercialization activities for Infinity's fatty acid amide hydrolase, or FAAH, program. The decision reflects progress made in the development of Infinity's oral FAAH inhibitor, IPI-940.

26 Oct 2010

New tools could help detect wildlife disease outbreaks

Two new tools that enable the public to report sick or dead wild animals could also lead to the detection and containment of wildlife disease outbreaks that may pose a health risk to people.

26 Oct 2010

Journal of Clinical Oncology publishes IPI-504 Phase 2 study results

Infinity Pharmaceuticals, Inc. announced that results from its Phase 2 study of IPI-504, a novel IV-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC) were published in the Journal of Clinical Oncology.

15 Oct 2010

Infinity announces preliminary results of IPI-926 Phase 1 study in patients with solid tumors

Infinity Pharmaceuticals, Inc. today announced promising preliminary results from a Phase 1 study of IPI-926, its novel, oral small molecule that targets the Hedgehog pathway.

11 Oct 2010

Knowledge about ecology of disease limits spread of infection

Common frog (Rana temporaria) populations across the UK are suffering dramatic population crashes due to infection from the emerging disease Ranavirus, reveals research published in the Zoological Society of London's (ZSL) journal Animal Conservation.

8 Oct 2010

Study explains importance of identifying global pandemic risk factors to predict spread of diseases

A recent study led by Dr. Parviez Hosseini, a senior research fellow from EcoHealth Alliance (formerly Wildlife Trust), explains the importance of identifying global pandemic risk factors as early as possible, in order to predict the spread of diseases like H1N1 "swine" flu and SARS. "Predictive Power of Air Travel and Socio-Economic data for Early Pandemic Spread," recently published in the scientific publication PLoS ONE, examines the interplay among travel, trade, and national healthcare resources in predicting the emergence and spread of H1N1 and other viruses.

7 Oct 2010

Albert Einstein College of Medicine receives grant to study role of proteins in health and disease

The National Institute of General Medical Sciences (NIGMS) has awarded Albert Einstein College of Medicine of Yeshiva University a five-year, $30 million grant to study the structure and function of thousands of biomedically important proteins.

1 Oct 2010

Infinity Pharmaceuticals to present IPI-926 inhibitor Phase 1 data at ESMO Congress

Infinity Pharmaceuticals, Inc. today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented during the 35th Congress of the European Society of Molecular Oncology (ESMO), in Milan, Italy.

23 Sep 2010

Infinity reports $18.4 million total revenue for second-quarter 2010

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today detailed recent developments in its product development portfolio and announced second quarter 2010 financial results.

4 Aug 2010

Infinity obtains global rights to Intellikine's portfolio of inhibitors of delta and gamma isoforms of PI3K

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, and Intellikine, Inc., a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, today announced an agreement under which Infinity obtained global development and commercialization rights to Intellikine's portfolio of inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase.

8 Jul 2010

Infinity commences enrollment in IPI-493 Phase 1 clinical trial for advanced hematologic malignancies

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that patients are being enrolled in a Phase 1 clinical trial evaluating IPI-493 in patients with advanced hematologic malignancies. This multi-center study is the second clinical trial of IPI-493, Infinity's oral heat shock protein 90 (Hsp90) chaperone inhibitor.

24 Jun 2010

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Infinity Pharmaceuticals, Inc. today reported the results from its Phase 2 clinical trial of IPI-504, the company's i.v.-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC). Data reported show that IPI-504 demonstrated clinical activity in patients with NSCLC, in particular among patients with oncogenic anaplastic lymphoma kinase (ALK) gene rearrangements.

4 Jun 2010

Infinity to present data from Hsp90 chaperone and Hedgehog pathway inhibitor programs at 2010 ASCO

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that data from its Hsp90 chaperone and Hedgehog pathway inhibitor programs will be presented during the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Ill. from June 4 through June 8, 2010.

21 May 2010

Ecological speciation linked to emergence of new fungal diseases in plants

A new commentary on the nature of pathogens is raising startling new questions about the role that fundamental science research on evolution plays in the understanding of emerging disease.

15 May 2010

Infinity Pharmaceuticals initiates Phase 1b/2 trial of IPI-926 Hedgehog pathway inhibitor for pancreatic cancer

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer.

22 Apr 2010

Vical awarded contract to conduct Phase 1 clinical trial of Vaxfectin-formulated DNA vaccine against A/H1N1

Vical Incorporated announced today that the U.S. Navy, through the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., has awarded Vical a contract to conduct a Phase 1 clinical trial of the company's Vaxfectin®-formulated DNA vaccine against A/H1N1 pandemic influenza (swine flu).

22 Mar 2010

PPD, Southern Research Institute collaborate in pandemic and seasonal influenza vaccine research

PPD and Southern Research Institute today announced they have formed a collaborative agreement in pandemic and seasonal influenza vaccine research and development to provide clients a full spectrum of influenza vaccine development services by collaborating on client bids and projects.

18 Mar 2010

Data from novel Hedgehog pathway inhibitor program to be presented at upcoming conferences

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that members of its senior leadership and scientific teams will be leading discussions and presenting data from its novel Hedgehog pathway inhibitor program – an emerging area of cancer research – at several upcoming conferences.

11 Mar 2010

Novel interventions for New World hemorrhagic fevers needed

New World hemorrhagic fevers are emerging infectious diseases found in South America that can cause terrible, Ebola-like symptoms. Current treatments are expensive and only partially effective.

9 Mar 2010

Hebrew University of Jerusalem receives $5 million grant from Bill & Melinda Gates Foundation

The Hebrew University of Jerusalem Kuvin Center for the Study of Infectious and Tropical Diseases has received a $5 million grant from the Bill & Melinda Gates Foundation for research into visceral leishmaniasis in Ethiopia.

17 Dec 2009